Syngene International Q4 Review - Higher Capex In FY22E To Impact Near-Term Profitability: Dolat Capital
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Syngene International Ltd. reported an operationally strong Q4 (32% Ebitda margins versus our estimate of 29%) despite an in-line top-line growth at 8% year-on-year (dollar term revenue growth 12%) led by discovery services and steady traction in dedicated research and development segment.
Ebitda margins at 32% (down 160 basis points YoY, up 340 basis points QoQ) driven by seasonality.
Two milestone developments in Q4 were:
Commercialisation at Mangalore facility with a small project and we expect large scale operations once the U.S. Food and Drug Administration inspection and approval comes through.
Extension of its long term contract with one of its oldest and largest customer, Bristol Myers Squibb, up to 2030.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.